Should I buy, hold, or sell HLF stock right now?

Herbalife Ltd. (HLF) currently earns a Roarable Rating of C (Hold — HOLD) with 64/100 RQD Confidence. Solid 78% profit margin (34% return on capital), mixed timing at 6x P/E—hold if owned, no rush to chase.

What is HLF's 12-month price target and RQD AI Jury consensus?

HLF's 12-month base price target is $13.64 (range $10.64 to $21.42), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Stock Ratings / Health Care / HLF

NUS (50) ZSTK (25) ESYN (38) CAH (73) ⌘ Pro Terminal →

Herbalife Ltd. (HLF) — RQD Stock Rating Cockpit

$13.28 +1.76% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.30

Herbalife Ltd. (HLF) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $1.37B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HLF Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HLF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Herbalife Ltd. (NYSE: HLF) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $13.28 (+1.76% 1D, market cap $1.37B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, HLF ranks #130 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HLF compare to NUS and ZSTK in the Health Care sector?

▼

Within the Health Care sector (Other Pharmaceuticals), HLF carries a Roarable C (64/100 RQD), trailing P/E of 5.9x, gross margin of 77.9%, and ROIC of 34.4%. By comparison, NUS (Nu Skin Enterprises Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC 6.7%, cap $226.3M) and ZSTK (ZeroStack Corp.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $60.7M). Among the 5-stock peer group, HLF leads on earnings multiple (5.9x) while HLF leads on capital efficiency (34.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HLF?

▼

Per HLF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001180262), Herbalife Ltd. generated $5.04B in revenue (+0.9% YoY), $228.3M in net income, and $252.9M in free cash flow against $2.79B in total assets and $1.97B in total debt. Key quantitative strengths: Strong cash generator (78% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $13.30 (+0.13%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE+2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HLF)Realized 20D OHLCV Swing Band: ±7.9%

Deterministic 5-Pillar Attribution (64/100 Composite)

🔍 WHY HLF SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 5% FCF Margin ($252.9M FCF) & 77.9% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (27% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$14.21-3.1% Next Q

Q2 (-2Q)

Grade B-$13.77-2.2% Next Q

Q3 (-1Q)

Grade B-$13.47-1.4% Next Q

Current

Grade C$13.28+1.1% Hist 90D α

Trajectory: B (72) → C (64)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the HLF Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 64/100 (C) score, HLF faces multiple-compression risk if 5.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($12.73) or 200D SMA ($13.97) invalidates the momentum regime and cuts Target Base ($13.64) toward Bear Floor ($10.64).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HLF• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HLF Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 64%NO 36%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

47.930 Oversold · 70 Hot

ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)

2.39>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

6 / 99-Pt Accounting

52-WEEK LASER RANGE44% OF RANGE

L: $8$13.28H: $20

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (78% profit margin and healthy balance-sheet cushion).

Factor Grade: ARQD 18 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: CRQD 25 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on HLF

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (90)

34.4% ROIC with 77.9% gross margin and 18.66% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (60)

Altman-Z 2.39 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (57)

25/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like HLF

✓Strong cash generator (78% profit margin)—profits are backed by real money, not accounting tricks.
✓Company leadership has skin in the game with net positive insider conviction.

Bear Case: What Could Go Wrong

!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (HLF Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HLF // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.06%📐 HORIZONTAL RANGE

2026-11-03O $12.93H $13.28L $12.93C $13.28VOL 1.52M

RES: $15.33SUP: $9.83SMA50: $12.73SMA200: $13.97

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HLF Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HLF Butterfly Map → + Track HLF →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

-11.1%/yr Implied 5Y Growth

vs. +0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on HLF today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HLF. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HLF today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HLF)

Health Care Rank #130 of 1016 ⚔️ NUS vs HLF Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HLF vs. NUS, ZSTK, ESYN, CAH)

Industry: Other Pharmaceuticals (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Herbalife Ltd. (HLF) ranks #130 by composite RQD confidence (64/100, grade C) and #312 by equity capitalization ($1.37B). Within this direct 5-issuer industry benchmark cohort, HLF leads on earnings valuation at 5.9x trailing P/E, while HLF leads on capital efficiency and profitability with 34.4% ROIC and 77.9% gross margin. CAH currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with HLF at 64/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HLF ACTIVE Herbalife Ltd.	C	64/100	5.9x	77.9%	34.4%	+1.76%	$1.37B	Benchmark Subject
NUS Nu Skin Enterprises Inc.	D	50/100	—	69.4%	6.7%	+2.80%	$226.3M	/nus-vs-hlf →
ZSTK ZeroStack Corp.	E	25/100	—	4.6%	-35.0%	-0.36%	$60.7M	/zstk-vs-hlf →
ESYN EnerSyn Global Inc.	D-	38/100	—	53.0%	-35.0%	-5.14%	$52.0M	/esyn-vs-hlf →
CAH Cardinal Health Inc.	B	73/100	37.2x	3.7%	29.7%	+1.54%	$58.00B	/cah-vs-hlf →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001180262

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Herbalife Ltd. (HLF) reported GAAP revenue of $5.04B (+0.9% vs. FY2024 revenue of $4.99B , and -0.5% cumulative change since FY2023) , GAAP net income of $228.3M, operating cash flow of $333.3M, and free cash flow of $252.9M (+54.8% YoY). On the balance sheet, HLF closed FY2025 with $2.79B in total assets against $1.97B in total debt (Altman Z-Score: 2.39, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$5.04B	$228.3M	$333.3M	$252.9M	$2.79B	$1.97B
FY2024 (FY)	2024-12-31	$4.99B	$254.3M	$285.4M	$163.4M	$2.73B	$1.98B
FY2023 (FY)	2023-12-31	$5.06B	$142.2M	$357.5M	$357.5M	—	—

3. HLF Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HLF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does HLF compare to NUS and ZSTK in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for HLF?

Where is HLF trading relative to its 50-day, 200-day, and 52-week technical levels?

HLF last traded at $13.28 (+1.76% on volume of 1,841,564 shares), positioning the stock +4.32% above its 50-day simple moving average ($12.73) and -4.94% below its 200-day simple moving average ($13.97). Across its 52-week range of $7.69 to $20.40, HLF sits at the 44.0% percentile with a 14-day RSI of 47.9 (NEUTRAL RANGE) and an implied next-earnings move of ±7.9% ($12.23 to $14.33).

Direct Sub-Reports: HLF RQD Cockpit HLF 12M Forecast HLF Earnings & Move HLF Dividends & DRIP HLF Insiders & 13F HLF Whale Options HLF Profit Sankey HLF News & Why

ROARABLE RATING BRIEF • RQD 64/100 (C) ✓ SEC XBRL & RQD VERIFIED

HLF — Herbalife Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Herbalife Ltd. (HLF) earns a live Roarable RQD composite score of 64/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $13.28 (+1.76% 1D, market capitalization $1.37B).

Fundamental Cash Engine (18/20): Anchored by return on invested capital (ROIC) of 34.4%, gross margin of 77.9%, operating margin of 9.5%, and free cash flow yield of 18.66%.
Whale 13F & Options Flow (8/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (9/20) + Forensic Balance Sheet (17/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.39, Piotroski F-Score of 6/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Herbalife Ltd. (HLF) is a NYSE-listed issuer in the Health Care sector and Other Pharmaceuticals industry,. Per the Market Data, the company reports a gross margin of 77.9%, an operating margin of 9.5%, and a net margin of 4.5%. — for product lines, customer segments, or specific revenue-generation mechanics.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Herbalife Ltd. (HLF) reported $5.04B in annual revenue (up from $4.99B in FY2024, +0.9% YoY) and $228.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($5.06B revenue, $142.2M net income) through FY2025, HLF scaled operating cash flow to $333.3M and free cash flow to $252.9M, backed by $2.79B in total assets against $1.97B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C • RQD 64/100): Strong cash generator (78% profit margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 18/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $7.69 – $20.40 52-week range.
🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 5.9x trailing P/E and 5.4x EV/EBITDA against 9.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are — The sector and industry classification (Health Care / Other Pharmaceuticals) is the only structural context provided.

Key Question #1: Can HLF sustain or expand its 9.5% operating margin and 34.4% ROIC against Other Pharmaceuticals peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $5.04B and free cash flow of $252.9M, how will capital allocation balance growth reinvestment against $1.97B in total debt?
Key Question #3: How sensitive is HLF's 5.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

HLF Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Herbalife Ltd. (HLF) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HLF Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 20h ago

Herbalife Ltd. (HLF) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GuruFocus • 23h ago

Herbalife Ltd (HLF) Shares Surge 4.5% -- What GF Score of 62 Tel

GuruFocus report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Benzinga • 1d ago

Top 3 Risk Off Stocks You May Want To Dump In Q4 - Herbalife (NYSE:HLF)

Benzinga report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Herbalife (HLF) Stock Could Sit Below Fair Value Today

Yahoo Finance report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST MarketBeat • 1d ago

Herbalife (NYSE:HLF) Stock Jumps 5% - Time to Buy?

MarketBeat report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Simply Wall St • 1d ago

How Investors Are Reacting To Herbalife (HLF) Slowing Sales Growth

Simply Wall St report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH The Globe and Mail • 1d ago

1 Surging Stock on Our Watchlist and 2 We Find Risky

The Globe and Mail report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockStory • 1d ago

1 Profitable Stock to Target This Week and 2 We Turn Down

StockStory report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HLF Bull vs. Bear Conversation Board — What's Your Call at $13.28?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HLF 🐻 33% BEARISH CONVICTION

TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $16.44 (+26.0%)

📌 Pinned Debate

Per the Roarable RQD rating, the Fundamental Cash Engine pillar scores 18 of 20 on ROIC of 34.4% and FCF yield of 18.66%, with a traili

Long HLF at $13.05 targeting $16.44. Per the Roarable RQD rating, the Fundamental Cash Engine pillar scores 18 of 20 on ROIC of 34.4% and FCF yield of 18.66%, with a trailing P/E of 5.9.. Institutional whale score is 8/20 and the risk/reward vs. the $7.69 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

Both sides have a point here — HLF's 12/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $10.18 (-22.0%)

Spot @ $13.05

Per the Roarable RQD rating, the Whale 13F Flow pillar scores only 8 of 20, and the Macro Regime Fit pillar scores 9 of 20 at a beta of

Here is the bear case nobody on the bull side wants to address on HLF: Per the Roarable RQD rating, the Whale 13F Flow pillar scores only 8 of 20, and the Macro Regime Fit pillar scores 9 of 20 at a beta of 1.0.. At 5.9x trailing P/E, even a small guidance miss in Other Pharmaceuticals triggers a 12-15% air pocket.